Its molecular diagnostics segment rose 18 percent year over year, and continued adoption of its prevention assays drove up sales of that business despite "a significant decline" in patient visits to doctors' offices in the US.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.